On November 12, 2026, Biocytogen successfully hosted Biocytogen Symposium Korea 2026 in Seoul, South Korea.
Under the theme “From Target to Clinic: AI-Driven Antibody Discovery and Advanced Preclinical Models for Next-Gen Therapeutics,” the symposium brought together industry experts, researchers, and biopharmaceutical professionals from across Korea to explore emerging technologies and innovative strategies for antibody drug discovery and development.
The symposium featured five scientific presentations delivered by Biocytogen’s scientific leaders:
Speaker: Benny (Yi) Yang, Ph.D., Chief Scientific Officer, Biocytogen
Speaker: Haipeng Liu, Ph.D., Head of ADC Platform, Biocytogen
Speaker: Meiqi Zhang, Ph.D., Head of BioMice Metabolic & Neuroscience Department, Biocytogen
Speaker: Yujie Liu, Ph.D., Director of Pharmacology Department, Biocytogen
Speaker: Zhen Chen, Ph.D., Head of the Autoimmune Pharmacology Department, Biocytogen
The symposium received an enthusiastic response from Korea’s biopharmaceutical community, with strong attendance and lively scientific discussions throughout the event.
The symposium received an enthusiastic response from Korea’s biopharmaceutical community, attracting approximately 100 registered participants, with strong attendance and lively scientific discussions throughout the event. Professionals from pharmaceutical companies, biotechnology companies, and research institutions gathered to exchange insights on innovative technologies, preclinical research strategies, and antibody therapeutic development. Engaging scientific presentations and active discussions deepened attendees’ understanding of Biocytogen’s fully human antibody discovery platforms and R&D capabilities, while creating valuable opportunities for future scientific exchange and research collaboration.
The successful conclusion of Biocytogen Symposium Korea 2026 marks another step forward in strengthening scientific exchange and collaboration between Biocytogen and Korea’s biopharmaceutical community.
Moving forward, Biocytogen will continue to leverage its innovative technology platforms and global R&D capabilities, working alongside partners in Korea and worldwide to accelerate the discovery and development of next-generation antibody therapeutics and advance its vision to become a global headstream of new drugs.